ArticleNature chemical biology2024
Template-assisted covalent modification underlies activity of covalent molecular glues.
Abstract read
In one paragraph
Article in Nature chemical biology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 57 papers.
0numbers the graph read from it
0cells of the map it votes in
57citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
57 citing papers in PubMed.
- Dual E3 ligase recruitment by monovalent degraders for tunable SMARCA 2/4 degradation.Nature chemical biology · 2026Article
- A tail of two ligases.Nature chemical biology · 2026Article
- High-throughput ligand diversification to discover chemical inducers of proximity.Nature chemical biology · 2026Article
- Article
- Charged molecular glue discovery enabled by targeted degron display.Nature chemical biology · 2026Article
- A New Recruitable E3 Ligase UHRF1 Supporting Targeted Protein Degradation: A Minimal Azide as a Recruitment Ligand.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Epidermal Growth Factor Receptor as a Model Drug Target for Scrutinizing the Status Quo in Drug Discovery and Chemical Biology.ACS bio & med chem Au · 2026Review
- Ubiquitin family as novel protein partners for molecular glues.npj drug discovery · 2026Review
- Proteomics-Driven Strategies for Proximity-Inducing Drug Discovery.Angewandte Chemie (International ed. in English) · 2026Review
- A destination-driven framework for nanoparticle-enabled targeted protein degradation.Acta pharmaceutica Sinica. B · 2026Review
- A Type II CDK6 Degrader Enables Cellular Targeting beyond the Limits of Type II Inhibition.Journal of the American Chemical Society · 2026Article
- Molecular glue degraders: Rational design, specificity engineering, and advanced delivery.Acta pharmaceutica Sinica. B · 2026Review
- Covalent Reprogramming of Kinase Binders to Modulate Protein Abundance.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Methods to Study the Molecular Mechanism and Drive the Design of Protein Degraders.Chemical reviews · 2026Review
- Discovery and Structural Optimization of BRD4-Selective Monovalent Direct Degraders.ACS medicinal chemistry letters · 2026Article
- BromoCatch: a self-labelling tag platform for protein modification and live cell imaging.Nature communications · 2026Article
- Harnessing FBXO31 with Terminal Amide-Functionalized Molecules for Targeted Protein Degradation.Journal of the American Chemical Society · 2026Article
- Neo-Cysteine Molecular Glues for Targeting Mutated SMAD4 Protein.Angewandte Chemie (International ed. in English) · 2026Article
- Small-molecule degraders for oncogenic KRASNature communications · 2026Article
- An Optimized RNF126-Targeting Covalent Handle for Molecular Glue Degraders.bioRxiv : the preprint server for biology · 2026Article
Corrections and comments
- Update of
Authors and funding
35 authors.
Yen-Der Li *Department of Molecular and Cellular Biology, Harvard University, Cambridge, MA, USA.
Michelle W Ma *Department of Molecular and Cellular Biology, Harvard University, Cambridge, MA, USA.
Muhammad Murtaza Hassan *Department of Chemical and Systems Biology, Chem-H and Stanford Cancer Institute, Stanford School of Medicine, Stanford University, Stanford, CA, USA.
Moritz HunkelerDepartment of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA, USA.ORCID 0000-0003-0246-1188
Mingxing TengCenter for Drug Discovery, Department of Pathology & Immunology, and Verna and Marrs McLean Department of Biochemistry and Molecular Pharmacology, Baylor College of Medicine, Houston, TX, USA.ORCID 0000-0001-6574-1764
Kedar PuvarDepartment of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA, USA.
Justine C RutterDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.ORCID 0000-0002-0851-0887
Ryan J LumpkinDepartment of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA, USA.
Brittany SandovalDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Cyrus Y JinDepartment of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA, USA.
Anna M SchmokerDepartment of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA, USA.ORCID 0000-0003-2830-5650
Scott B FicarroDepartment of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA, USA.
Hakyung CheongDepartment of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA, USA.
Rebecca J MetivierDepartment of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA, USA.ORCID 0000-0001-9929-6857
Michelle Y WangDepartment of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA, USA.
Shawn XuDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Woong Sub ByunDepartment of Chemical and Systems Biology, Chem-H and Stanford Cancer Institute, Stanford School of Medicine, Stanford University, Stanford, CA, USA.ORCID 0000-0003-4676-3698
Brian J GroendykeDepartment of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA, USA.
Inchul YouDepartment of Chemical and Systems Biology, Chem-H and Stanford Cancer Institute, Stanford School of Medicine, Stanford University, Stanford, CA, USA.
Logan H SiguaDepartment of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA, USA.
Isidoro TavaresDepartment of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA, USA.
Charles ZouDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Jonathan M TsaiDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Paul M C ParkDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.ORCID 0000-0002-9380-8548
Hojong YoonDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Felix C MajewskiDepartment of Chemical and Systems Biology, Chem-H and Stanford Cancer Institute, Stanford School of Medicine, Stanford University, Stanford, CA, USA.ORCID 0000-0001-5330-5922
Haniya T SperlingDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.ORCID 0009-0006-6624-1597
Jarrod A MartoDepartment of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA, USA.ORCID 0000-0003-2086-1134
Jun QiDepartment of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA, USA.ORCID 0000-0002-1461-3356
Radosław P NowakDepartment of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA, USA.ORCID 0000-0002-0605-0071
Katherine A DonovanDepartment of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA, USA.ORCID 0000-0002-8539-5106
Mikołaj SłabickiDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.ORCID 0000-0001-6317-9296
Nathanael S GrayDepartment of Chemical and Systems Biology, Chem-H and Stanford Cancer Institute, Stanford School of Medicine, Stanford University, Stanford, CA, USA. nsgray01@stanford.edu.ORCID 0000-0001-5354-7403
Eric S FischerDepartment of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA, USA. eric_fischer@dfci.harvard.edu.ORCID 0000-0001-7337-6306
Benjamin L EbertDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA. benjamin_ebert@dfci.harvard.edu.ORCID 0000-0003-0197-5451
Funding
TYROSINE KINASE ONCOGENESIS IN MYELOID LEUKEMIAP01CA066996 · NCI · DANA-FARBER CANCER INSTITUTE · PI SCOTT A ARMSTRONG · 1996 to 2026
$52.5MMedical Scientist Training ProgramT32GM144273 · NIGMS · HARVARD MEDICAL SCHOOL · PI David Shumway Jones, Jacqueline A. Lees · 2022 to 2026
$14.7MIlluminating Function of the Understudied Druggable KinomeU24DK116204 · NIDDK · UNIV OF NORTH CAROLINA CHAPEL HILL · PI JOHNSON, GARY L. · 2017 to 2022
$13.6MTargeting SYK Kinase in AMLP50CA206963 · NCI · DANA-FARBER CANCER INST · PI GRAUBERT, TIMOTHY A · 2017 to 2021
$10.6MFunctional Genomic Dissection of Refractory AnemiaR01HL082945 · NHLBI · DANA-FARBER CANCER INSTITUTE · PI EBERT, BENJAMIN LEVINE · 2005 to 2022
$6.8MThe role of clonal hematopoiesis in the development and therapy of myeloid malignanciesR35CA253125 · NCI · DANA-FARBER CANCER INST · PI EBERT, BENJAMIN LEVINE · 2020 to 2024
$4.9M(PQ5) Contribution of mitochondrial pathways to metabolic heterogeneity in molecular subtypes of Diffuse Large B Cell LymphomaR01CA219850 · NCI · DANA-FARBER CANCER INST · PI DANIAL, NIKA N, MARTO, JARROD A. · 2018 to 2022
$2.8MCancer Chemical Biology and Metabolism Training ProgramT32CA236754 · NCI · DANA-FARBER CANCER INST · PI Nika N Danial, THOMAS M ROBERTS · 2019 to 2026
$2.6MNovel Screening Platform for Discovery of DUB Targeting ProbesR01CA233800 · NCI · DANA-FARBER CANCER INST · PI BUHRLAGE, SARA J, MARTO, JARROD A. · 2019 to 2022
$2.5M(PQ5) Microenvironmental Regulation of Mitochondrial Heterogeneity in Cancer MetastasisR01CA220012 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI SHEN, KEYUE · 2019 to 2023
$2.2MDevelopment of a generalizable chemo-proteomics screening platform for small molecule degraders applied to HDACsR01CA262188 · NCI · DANA-FARBER CANCER INST · PI FISCHER, ERIC SEBASTIAN · 2022 to 2025
$1.8M500 MHz NMR Spectrometer System with High Sensitivity Cryoprobe and Automated Sample Changer for Biochemical ResearchS10OD028697 · OD · STANFORD UNIVERSITY · PI BURNS, NOAH ZACHARY · 2020 to 2020
$709kCancer Prevention and Research Institute of Texas (Cancer Prevention Research Institute of Texas) RR220012NCI NIH HHS K00 CA253754NCI NIH HHS K99 CA287069NCI NIH HHS P01 CA066996NCI NIH HHS P50 CA206963NCI NIH HHS R01 CA219850NCI NIH HHS R01 CA233800NCI NIH HHS R01 CA262188NCI NIH HHS R21 CA247671NCI NIH HHS R35 CA253125NCI NIH HHS T32 CA236754NHLBI NIH HHS R01 HL082945NIDDK NIH HHS U24 DK116204NIGMS NIH HHS T32 GM144273NIH HHS S10 OD028697U.S. Department of Health & Human Services | National Institutes of Health (NIH) 1S10OD028697-01U.S. Department of Health & Human Services | National Institutes of Health (NIH) K00CA253754U.S. Department of Health & Human Services | National Institutes of Health (NIH) K99CA287069U.S. Department of Health & Human Services | National Institutes of Health (NIH) P01CA066996U.S. Department of Health & Human Services | National Institutes of Health (NIH) P50CA206963U.S. Department of Health & Human Services | National Institutes of Health (NIH) R01CA219850U.S. Department of Health & Human Services | National Institutes of Health (NIH) R01CA233800U.S. Department of Health & Human Services | National Institutes of Health (NIH) R01CA262188U.S. Department of Health & Human Services | National Institutes of Health (NIH) R01HL082945U.S. Department of Health & Human Services | National Institutes of Health (NIH) R21CA247671U.S. Department of Health & Human Services | National Institutes of Health (NIH) R35CA253125U.S. Department of Health & Human Services | National Institutes of Health (NIH) U24DK116204
Abstract
Molecular glues are proximity-inducing small molecules that have emerged as an attractive therapeutic approach. However, developing molecular glues remains challenging, requiring innovative mechanistic strategies to stabilize neoprotein interfaces and expedite discovery. Here we unveil a trans-labeling covalent molecular glue mechanism, termed 'template-assisted covalent modification'. We identified a new series of BRD4 molecular glue degraders that recruit CUL4
Indexed as
Cell Cycle ProteinsTranscription FactorsBromodomain Containing ProteinsHEK293 CellsHumansModels, MolecularProtein BindingProteolysisBRD4 protein, humanBromodomain Containing ProteinsCell Cycle ProteinsTranscription Factors
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.